EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+12.44%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.31B
AUM Growth
+$1.31B
(+3.9%)
Cap. Flow
-$33.1M
Cap. Flow
% of AUM
-2.52%
Top 10 Holdings %
Top 10 Hldgs %
65.03%
Holding
329
New
20
Increased
146
Reduced
123
Closed
37
Top Buys
| 1 |
KLA
KLAC
|
$9.71M |
| 2 |
Pinduoduo
PDD
|
$8.56M |
| 3 |
iShares Gold Trust
IAU
|
$3.24M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.14M |
| 5 |
iShares MSCI Global Gold Miners ETF
RING
|
$3.08M |
Top Sells
| 1 |
Grab
GRAB
|
$40.9M |
| 2 |
NVIDIA
NVDA
|
$7.48M |
| 3 |
Microsoft
MSFT
|
$5.75M |
| 4 |
STAAR Surgical
STAA
|
$4.82M |
| 5 |
Sea Limited
SE
|
$3.38M |
Sector Composition
| 1 | Consumer Discretionary | 45.37% |
| 2 | Technology | 25.37% |
| 3 | Communication Services | 8.93% |
| 4 | Healthcare | 6.43% |
| 5 | Real Estate | 6.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
DexCom
DXCM
$29.5B
| $477K | 0.04% |
5,115
+819
| +19% | +$76.4K |
|
127
Home Depot
HD
$405B
| $474K | 0.04% |
1,569
-123
| -7% | -$37.2K |
|
128
Neurocrine Biosciences
NBIX
$13.8B
| $471K | 0.04% |
4,185
-598
| -13% | -$67.3K |
|
129
Roper Technologies
ROP
$56.6B
| $470K | 0.04% |
970
-76
| -7% | -$36.8K |
|
130
Chevron
CVX
$324B
| $467K | 0.04% |
2,769
-142
| -5% | -$23.9K |
|
131
Keurig Dr Pepper
KDP
$39.5B
| $466K | 0.04% |
14,752
+2,835
| +24% | +$89.6K |
|
132
Sarepta Therapeutics
SRPT
$1.78B
| $462K | 0.04% |
3,814
+315
| +9% | +$38.2K |
|
|
IMGN
133
DELISTED
Immunogen Inc
IMGN
| $462K | 0.04% |
29,125
+10,992
| +61% | +$174K |
|
134
United Therapeutics
UTHR
$13.8B
| $459K | 0.03% |
2,032
+77
| +4% | +$17.4K |
|
135
Biohaven
BHVN
$1.63B
| $458K | 0.03% |
17,608
+7,415
| +73% | +$193K |
|
|
HZNP
136
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $458K | 0.03% |
3,962
-539
| -12% | -$62.3K |
|
137
Amphenol
APH
$133B
| $455K | 0.03% |
5,416
-399
| -7% | -$33.5K |
|
138
Halozyme
HALO
$8.56B
| $454K | 0.03% |
11,874
-1,278
| -10% | -$48.9K |
|
139
Exelixis
EXEL
$10.1B
| $452K | 0.03% |
20,682
-2,581
| -11% | -$56.4K |
|
140
Paychex
PAYX
$50.2B
| $450K | 0.03% |
3,903
+596
| +18% | +$68.7K |
|
141
BioMarin Pharmaceuticals
BMRN
$11.2B
| $449K | 0.03% |
5,070
+181
| +4% | +$16K |
|
142
Copart
CPRT
$47.2B
| $446K | 0.03% |
10,349
+6,066
| +142% | +$261K |
|
143
Alkermes
ALKS
$4.78B
| $444K | 0.03% |
15,850
+1,502
| +10% | +$42.1K |
|
144
Thermo Fisher Scientific
TMO
$186B
| $444K | 0.03% |
876
+50
| +6% | +$25.3K |
|
145
Amicus Therapeutics
FOLD
$2.34B
| $442K | 0.03% |
36,377
+1,510
| +4% | +$18.3K |
|
|
SAGE
146
DELISTED
Sage Therapeutics
SAGE
| $435K | 0.03% |
21,160
+13,703
| +184% | +$282K |
|
147
Recursion Pharmaceuticals
RXRX
$2.04B
| $434K | 0.03% |
56,732
+39,503
| +229% | +$302K |
|
148
Ironwood Pharmaceuticals
IRWD
$214M
| $432K | 0.03% |
44,896
+5,907
| +15% | +$56.8K |
|
149
Kraft Heinz
KHC
$33.1B
| $432K | 0.03% |
12,834
+2,311
| +22% | +$77.8K |
|
|
BPMC
150
DELISTED
Blueprint Medicines
BPMC
| $430K | 0.03% |
8,565
+926
| +12% | +$46.5K |
|